RxDoctor Payments Data

Jason Falcone

Medical · Syracuse, NYNPI 1487615571

Payments from drug & device makers

$5,358in general payments, 2019–2025

Across 211 payments — averaging $25.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$810
  • Astellas Pharma US Inc$552
  • Myriad Genetic Laboratories, Inc.$401
  • Johnson & Johnson$306
  • Antares Pharma, Inc.$289
  • Urovant Sciences Inc$236
  • plus $3K from 38 others

What the payments were for

  • Travel & lodging$65612%
  • Food & beverage$4,42383%
  • Education$2795%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,358 in reported general payments places this provider in the 90th percentile of 2,395 medical providers in New York.

See all medical providers in New York

Medicare billing

Part B allowed, 2024
$47,297
Medicare patients
358
Services billed
1,109

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron157$99,869
MyrbetriqMirabegron118$78,428
Mirabegron ErMirabegron19$12,698
Silodosin185$12,468
Tamsulosin Hcl552$6,138
Potassium Citrate ErPotassium Citrate77$4,746
Testosterone43$3,649
Methenamine Hippurate58$3,116
Finasteride218$2,421
Alfuzosin Hcl ErAlfuzosin Hcl121$2,282
Tadalafil16$1,579
Dutasteride30$1,385
Solifenacin Succinate28$1,340
Estradiol16$1,268
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip30$1,020

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$221$99,869157 claims
Astellas Pharma US IncMyrbetriq$552$78,428118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,395 medical providers in New York.

Other medical in Syracuse

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →